Treatment of Fuchs Disease: Review of Clinical Trials

Authors

  • Tiago Rezende Savian Hospital Irmandade Santa Casa de Misericórdia de Santos
  • Nelson Monteiro da Silva Hospital Irmandade Santa Casa de Misericórdia de Santos
  • Saulo Yudi Sakashita Hospital Irmandade Santa Casa de Misericórdia de Santos
  • Guilherme Vita Pôncio de Lacerda Ribeiro Hospital Irmandade Santa Casa de Misericórdia de Santos
  • Giovanna Sabage Hospital Irmandade Santa Casa de Misericórdia de Santos
  • Pedro Henrique Fragoso Alves Hospital Irmandade Santa Casa de Misericórdia de Santos
  • Raphael Macedo de Melo Silva Hospital Irmandade Santa Casa de Misericórdia de Santos
  • Beatriz Queiroga Victor Hospital Irmandade Santa Casa de Misericórdia de Santos

DOI:

https://doi.org/10.37497/ijhmreview.v8i1.306

Keywords:

Fuchs Endothelial Corneal Dystrophy, Descemet's Membrane, Treatment

Abstract

Background: Fuchs corneal endothelial dystrophy (FECD) is a genetically heterogeneous disease, accompanied by irreparable damage to the corneal endothelium. FECD is characterized by thickening of Descemet's membrane, with accelerated loss of endothelial cells initially in the center of the cornea and later in its periphery. A mosaic defect of the endothelium of the corneal surface in which cells respond with proliferation and migration, resulting in non-uniform abnormalities in size (polymegatism) and variations in hexagonal shape (pleomorphism). The most recent International Classification of Corneal Dystrophies categorizes FECD into two types: 1 - early-onset FECD (rare); and 2 - late-onset FECD (most common). Aim: To carry out a literature review to synthesize the clinical evidence related to the treatments of FECD. Method: Papers were selected in PubMed databases using the following search strategy: fuchs[title] AND dystrophy[title]. Only clinical trials published in the last five years were considered in this review. Results: Eleven articles were selected that adequately discuss treatments and disease management strategies. Synthesis of the Evidence: The main method of treatment for FECD is Descemet's membrane endothelial keratoplasty (DMEK), considered the gold standard for the management of disease. In addition, several tools and strategies capable of improving the parameters related to the procedure, or even allowing the evaluation of the evolution of teaching, are presented.

Author Biographies

Tiago Rezende Savian, Hospital Irmandade Santa Casa de Misericórdia de Santos

Residência Médica em Oftalmologia.

Nelson Monteiro da Silva, Hospital Irmandade Santa Casa de Misericórdia de Santos

Residência Médica em Oftalmologia.

Saulo Yudi Sakashita, Hospital Irmandade Santa Casa de Misericórdia de Santos

Residência Médica em Oftalmologia.

Guilherme Vita Pôncio de Lacerda Ribeiro, Hospital Irmandade Santa Casa de Misericórdia de Santos

Residência Médica em Oftalmologia.

Giovanna Sabage, Hospital Irmandade Santa Casa de Misericórdia de Santos

Residência Médica em Oftalmologia.

Raphael Macedo de Melo Silva, Hospital Irmandade Santa Casa de Misericórdia de Santos

Residência Médica em Oftalmologia.

Beatriz Queiroga Victor, Hospital Irmandade Santa Casa de Misericórdia de Santos

Residência Médica em Oftalmologia.

Published

2022-04-07

How to Cite

Savian, T. R., Silva, N. M. da, Sakashita, S. Y., Ribeiro, G. V. P. de L., Sabage, G., Alves, P. H. F., Silva, R. M. de M., & Victor, B. Q. (2022). Treatment of Fuchs Disease: Review of Clinical Trials. International Journal of Health Management Review, 8(1). https://doi.org/10.37497/ijhmreview.v8i1.306

Issue

Section

Artigos